192869-24-2Relevant academic research and scientific papers
Process for the production of quinazolines
-
, (2008/06/13)
The invention provides a process for the production of a compound of formula (A), or a pharmaceutically acceptable salt or solvate thereof, wherein R1 represents C1-4 alkoxy optionally substituted by one or more fluorine atoms; Rsup
Quinoline and quinazoline compounds useful in therapy, particularly in the treatment of benign prostatic hyperplasia
-
, (2008/06/13)
Compounds of formula I, STR1whereinR 1 represents C 1-4 alkoxy optionally substituted by one or more fluorine atoms;R 2 represents H or C 1-6 alkoxy optionally substituted by one or more fluorine atoms;R 3 represents a 5- or 6-membered heterocyclic ring, the ring being optionally substituted;R 4 represents a 4-, 5-, 6-, or 7-membered heterocyclic ring, the ring being optionally fused to a benzene ring or a 5- or 6-membered heterocyclic ring, the ring system as a whole being optionally substituted;X represents CH or N; andL is absent,or represents a cyclic group of formula Ia, STR2or represents a chain of formula Ib, STR3and pharmaceutically acceptable salts thereof, are useful in therapy, in particular in the treatment of benign prostatic hyperplasia.
Quinoline and quinazoline compounds useful in therapy
-
, (2008/06/13)
PCT No. PCT/EP96/05609 Sec. 371 Date Jun. 17, 1998 Sec. 102(e) Date Jun. 17, 1998 PCT Filed Dec. 5, 1996 PCT Pub. No. WO97/23462 PCT Pub. Date Jul. 3, 1997The invention provides compounds of formula (I), wherein R1 represents C1-4 alkoxy optionally substituted by one or more fluorine atoms; R2 represents H or C1-6 alkoxy optionally substituted by one or more fluorine atoms; R3 represents one or more groups independently selected from H, halogen, C1-4 alkoxy and CF3; in addition, R2 and one R3 group may together represent -OCH2-, the methylene group being attached to the ortho-position of the pendant phenyl ring; R4 represents a 4-, 5- or 6-membered heterocyclic ring containing 1 or 2 heteroatoms selected from N, O and S, the ring being optionally fused to a benzene ring or a 5- or 6-membered heterocyclic ring containing 1 or 2 heteroatoms selected from N, O and S, the ring system as a whole being optionally substituted; X represents CH or N; and L is absent or represents a cyclic group or an open chain group; and pharmaceutically acceptable salts thereof. The compounds of formula (I) are useful in the treatment of inter alia benign prostatic hyperplasia.
